Certara (NASDAQ:CERT) Price Target Lowered to $13.00 at Robert W. Baird

Certara (NASDAQ:CERT) had its price target trimmed by Robert W. Baird from $18.00 to $13.00 in a report published on Tuesday,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other research firms have also recently commented on CERT. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. KeyCorp reduced their target price on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Barclays lowered their price target on Certara from $16.00 to $14.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 15th. Finally, JMP Securities reiterated a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Certara currently has an average rating of “Hold” and an average target price of $15.92.

Certara Trading Up 0.7 %

Certara stock opened at $10.99 on Tuesday. Certara has a 12 month low of $9.99 and a 12 month high of $19.87. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The business’s fifty day simple moving average is $11.07 and its two-hundred day simple moving average is $13.75. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -21.98, a price-to-earnings-growth ratio of 4.88 and a beta of 1.51.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. As a group, equities analysts predict that Certara will post 0.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. purchased a new position in Certara during the second quarter valued at approximately $26,000. Innealta Capital LLC bought a new stake in shares of Certara during the 2nd quarter valued at $36,000. KBC Group NV lifted its stake in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after buying an additional 1,584 shares in the last quarter. Intech Investment Management LLC bought a new position in Certara in the 2nd quarter worth $152,000. Finally, Algert Global LLC purchased a new stake in Certara in the 2nd quarter worth $156,000. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.